Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
- Schneeweiss, A.
- Park-Simon, T.-W.
- Albanell, J.
- Lassen, U.
- Cortés, J.
- Dieras, V.
- May, M.
- Schindler, C.
- Marmé, F.
- Cejalvo, J.M.
- Martinez-Garcia, M.
- Gonzalez, I.
- Lopez-Martin, J.
- Welt, A.
- Levy, C.
- Joly, F.
- Michielin, F.
- Jacob, W.
- Adessi, C.
- Moisan, A.
- Meneses-Lorente, G.
- Racek, T.
- James, I.
- Ceppi, M.
- Hasmann, M.
- Weisser, M.
- Cervantes, A.
- Montrer des auteurs +
ISSN: 1573-0646, 0167-6997
Année de publication: 2018
Volumen: 36
Número: 5
Pages: 848-859
Type: Article